Phase IIa Data on TMC435350 in Patients with Hepatitis C

[Guest guest]

http://www.therapeuticsdaily.com/news/summary.cfm?id=1862446 & channelID=31

Phase IIa Data on TMC435350 in Patients with Hepatitis C Now Presented at t..

Cision (English) - 4-Nov-2008

Medivir has today together with its partner Tibotec presented data from the

ongoing phase IIa trial with TMC435350. TMC435350 is an investigational protease

inhibitor, being developed by Tibotec in partnership with Medivir, for the

treatment of hepatitis C virus (HCV). In more than 60% of these cases, the HCV

infection leads to chronic liver disease, cirrhosis and liver tumors.

Summary

• Medivir has today together with its partner Tibotec presented data from the

ongoing phase IIa trial with TMC435350.

• These data were presented at the 59th Annual Meeting of the American

Association for Study of Liver Diseases (AASLD) meeting in San Francisco held

between October 31 - November 4.

• TMC435350 is an investigational protease inhibitor, being developed by Tibotec

in partnership with Medivir, for the treatment of hepatitis C virus (HCV).

• Clinical results from the ongoing phase IIa trial (OPERA-1) have now been

presented in two posters and a third poster will present preclinical results.

• These posters are now available on our website;

• www.medivir.se under: IR & Media / Latest events

• Tibotec has also published a press release with a summery of the data

presented at this congress.

• This press release is to be found on our website under IR & Media / Latest

events.

[Guest guest]

http://www.therapeuticsdaily.com/news/summary.cfm?id=1862446 & channelID=31

Phase IIa Data on TMC435350 in Patients with Hepatitis C Now Presented at t..

Cision (English) - 4-Nov-2008

Medivir has today together with its partner Tibotec presented data from the

ongoing phase IIa trial with TMC435350. TMC435350 is an investigational protease

inhibitor, being developed by Tibotec in partnership with Medivir, for the

treatment of hepatitis C virus (HCV). In more than 60% of these cases, the HCV

infection leads to chronic liver disease, cirrhosis and liver tumors.

Summary

• Medivir has today together with its partner Tibotec presented data from the

ongoing phase IIa trial with TMC435350.

• These data were presented at the 59th Annual Meeting of the American

Association for Study of Liver Diseases (AASLD) meeting in San Francisco held

between October 31 - November 4.

• TMC435350 is an investigational protease inhibitor, being developed by Tibotec

in partnership with Medivir, for the treatment of hepatitis C virus (HCV).

• Clinical results from the ongoing phase IIa trial (OPERA-1) have now been

presented in two posters and a third poster will present preclinical results.

• These posters are now available on our website;

• www.medivir.se under: IR & Media / Latest events

• Tibotec has also published a press release with a summery of the data

presented at this congress.

• This press release is to be found on our website under IR & Media / Latest

events.